Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults

Section: Surgery
Effective Date: July 01, 2018
Revised Date: November 12, 2019
Last Reviewed: November 14, 2019


Hematopoietic cell transplantation (HCT) refers to a procedure in which hematopoietic cells are infused to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of cytotoxic drugs with or without whole body radiation therapy. Hematopoietic cells may be obtained from the transplant recipient (autologous HCT) or from a donor (allogeneic HCT).


Autologous or allogeneic cell transplant is considered experimental/investigational for the following malignancies in adults:

  • Cancer of the bile duct
  • Cancer of the fallopian tubes
  • Cervical cancer
  • Colon cancer
  • Esophageal cancer
  • Gall bladder cancer
  • Lung cancer, any histology
  • Malignant melanoma
  • Nasopharyngeal cancer
  • Neuroendocrine tumors
  • Pancreas cancer
  • Paranasal sinus cancer
  • Prostate cancer
  • Rectal cancer
  • Renal cell cancer
  • Soft tissue sarcomas
  • Stomach cancer
  • Thyroid tumors
  • Tumors of the thymus
  • Tumors of unknown primary origin
  • Uterine cancer

There is inadequate evidence in peer-reviewed medical literature demonstrating the effectiveness of autologous or allogeneic cell transplantation, therefore, this procedure is not covered.

Procedure Codes

38205 38206 38220 38221 38222 38240 38241